

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cost-Utility of Sofosbuvir/Velpatasvir for Chronic Hepatitis C Genotype 1b Infection in China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035224
Article Type:	Original research
Date Submitted by the Author:	23-Oct-2019
Complete List of Authors:	Yun, Haoya; Shandong University, School of Health Care Management; NHC Key Laboratory of Health Economics and Policy Research (Shandong University) Zhao, Guoqiang; Shandong University, School of Health Care Management; NHC Key Laboratory of Health Economics and Policy Research (Shandong University) Sun, Xiaojie; Shandong University, School of Health Care Management; NHC Key Laboratory of Health Economics and Policy Research (Shandong University) Shi, Lizheng; Tulane University, Department of Health Policy and Management, School of Public Health and Tropical Medicine
Keywords:	HEALTH ECONOMICS, Hepatology < INTERNAL MEDICINE, Public health < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Cost-Utility of Sofosbuvir/Velpatasvir for Chronic Hepatitis C Genotype 1b Infection in China

Haoya Yun^{1,2}, Guoqiang Zhao^{1,2}, Xiaojie Sun^{1,2*}, Lizheng Shi³

1 School of Health Care Management, Shandong University, Jinan 250012, China

2 NHC Key Laboratory of Health Economics and Policy Research (Shandong University), Jinan 250012, China

3 Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70118, USA

*Correspondence:

Xiaojie Sun, PhD, School of Health Care Management, Shandong University and NHC Key Laboratory of Health Economics and Policy Research (Shandong University). Address: 44 Wenhua Xi Road, Jinan, Shandong Province, 250012, People's Republic of China.

E-mail: xiaojiesun@sdu.edu.cn. Tel: 86-15153169185

Keywords: cost-utility, Markov model, sofosbuvir/velpatasvir, chronic hepatitis c

Word count: 2852 words

Abstract

Objective This study aimed to estimate the cost-utility of sofosbuvir/velpatasvir (SOF/VEL) compared with other direct-acting antivirals (DAAs) in Chinese HCV patients.

Methods A state-transition Markov model was developed to estimate the disease progression of HCV genotype 1b patients over a lifetime horizon. From the health care system perspective, the model measured the lifetime costs, quality-adjusted life years (QALYs) and incremental cost-utility ratio (ICURs) of SOF/VEL versus sofosbuvir + ribavirin (SR), sofosbuvir + dasabuvir (SD), daclatasvir + asunaprevir (DCV/ASV), ombitasvir/paritaprevir/ritonavir + dasabuvir (3D), and elbasvir/grazoprevir (EBR/GZR). SVR rates, clinical inputs and utilities were derived from published literature. The medical costs consisted of drug costs and health costs for Markov health states. Drug costs were from the market price survey, and health costs for Markov health states were sourced from a Chinese study. Costs and utilities were discounted at an annual rate of 5%. One-way and probabilistic sensitivity analyses were conducted to test the impact of input parameters on the results.

Results SOF/VEL was economically dominant over SR and SD. However, 3D was economically dominant versus SOF/VEL. Compared to DCV/ASV, SOF/VEL was cost-effective with the ICUR of

1
2
3
4 \$1522 per QALY. Compared to EBR/GZR, it was not cost-effective with the ICUR of \$369,627 per
5 QALY. One-way sensitivity analysis demonstrated that reducing the cost of SOF/VEL to the lower
6 value of confidence interval, resulted in dominance over EBR/GZR and 3D. Probabilistic sensitivity
7 analysis demonstrated that 3D was cost-effective in 100% of iterations in GT1b patients and SOF/VEL
8 was not cost-effective.
9

10
11
12
13 **Conclusions** Compared with other oral direct-acting antiviral agents, SOF/VEL treatment was not the
14 most cost-effectiveness option for patients with chronic HCV GT1b in China. Lower the price of
15 SOF/VEL will make it cost-effective while simplifying treatment and achieving the goal of HCV
16 elimination.
17
18
19

20 21 **Strengths and limitations of this study**

22
23 To our knowledge, this is the first study including all available all-oral DAAs for the treatment of HCV
24 1b patients and comparing the cost-effectiveness of SOF/VEL with all other DAAs in the Chinese
25 setting.
26
27

28
29 The findings have direct relevance to policy decision makers considering the health policy to
30 incorporate DAAs into the healthcare system.
31

32
33 Some of the parameters were retrieved from published literature due to the absence of the real-world
34 data in China, which may result in some bias on our results.
35

36
37 Only the HCV genotype 1b was considered in this study, other genotypes were not included, which
38 may restrict the generalibility of findings in this study.
39

40 41 **Introduction**

42
43 Chronic hepatitis C (CHC) is a major public health problem worldwide. It is estimated that there are
44 around 71 million individuals chronically infected with HCV, leading to approximately 399,000 deaths
45 each year.[1, 2] In China, the number of HCV-infected patients was estimated to be approximate 10
46 million in 2006, and the most prevalent genotype is HCV genotype (GT) 1b.[3, 4] The Chinese Center
47 for Disease Control and Prevention reported that the incidence was showing an increasing trend, with
48 an estimated 200,000 new cases annually from 2014 to 2018. The undiagnosed and untreated chronic
49 HCV-infected patients are likely to develop serious liver-related complications such as decompensated
50 cirrhosis (DC) and hepatocellular carcinoma (HCC), leading to substantial clinical and economic
51 burden.[5, 6]
52
53
54
55
56
57
58
59
60

1
2
3
4 The endpoint of treating HCV infection is achieving sustained virologic response (SVR), which can
5 significantly reduce the risk of liver disease progression and avoid conversion to end-stage liver
6 diseases.[7] Patients achieving SVR are associated with lower costs and improved quality of life.[8]
7
8 Therefore, the treatment of HCV and achievement of SVR are of critical significance in reducing the
9 health and economic burdens among CHC patients.
10
11

12
13 For decades, the standard of care for HCV-infected patients in china has been based on pegylated
14 interferon plus ribavirin (PR) therapy, which is associated with low efficacy, long treatment durations,
15 poor tolerability and much adverse event rates, especially in cirrhotic patients.[9] The introduction of
16 direct-acting antivirals (DAAs), with improved SVR and fewer side effects, has revolutionized HCV
17 treatment. The latest Chinese guideline has suggested that DAA regimens should be applied if patients
18 could afford medical expenses.[9] In recent years, a range of drugs have been approved for HCV
19 treatment by the Chinese State Food and Drug Administration (CFDA). These all-oral regimens for
20 HCV-infected patients, including sofosbuvir plus ribavirin (SR), sofosbuvir plus daclatasvir (SD),
21 daclatasvir plus asunaprevir (DCV/ASV), ombitasvir/paritaprevir/ritonavir plus dasabuvir (3D),
22 elbasvir/grazoprevir (EBR/GZR), and sofosbuvir/velpatasvir (SOF/VEL), have been currently available
23 in China. All these interferon-free regimens resulted in higher efficacy and shorter duration, compared
24 with interferon-based regimens.[10,11] Specially, SOF/VEL was listed in the National Essential
25 Medicines List of China as the only full-oral, direct anti-HCV drug in 2018. Unlike other DAAs,
26 SOF/VEL is a pan-genotypic drug, which is the first fixed-dosage regimen able to achieve high rates of
27 SVR, after only 12 weeks of treatment across all genotypes, all fibrosis scores and typologies of
28 patients.[12]
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 At the present, it is not clear whether SOF/VEL is cost-effective in Chinese HCV GT1b patients.
45 Therefore, the objective of this study was to estimate the cost-effectiveness of SOF/VEL compared
46 with other available DAA regimens for treatment of hepatitis HCV GT1b patients.
47
48
49

50 **Methods**

51 We used a state-transition Markov model to estimate the economic benefits of SOF/VEL regimen in
52 Chinese patients with HCV GT1b, from the health care system perspective. The model simulated the
53 disease progression of HCV patients who received treatment with SOF/VEL or comparators. The
54 model used an annual cycle length and a lifetime horizon. A discount rate of 5% was used for costs and
55
56
57
58
59
60

1
2
3
4 utilities in this model.

5 **Patients characteristics**

6
7 The base-case population in the model represented treatment-naïve patients infected with HCV GT1b,
8 the major genotype in China. According to a Chinese study, the mean age of Chinese HCV-infected
9 patients were 44.5 years,[4] so it was assumed that the patients entered the model at the age of 45 years
10 old in this study. The baseline distribution was defined by the METAVIR fibrosis stages: no fibrosis
11 (F0), portal fibrosis with no septa (F1), portal fibrosis with few septa (F2), numerous septa without
12 cirrhosis (F3), and compensated cirrhosis (F4).[13] Based on another Chinese investigation,[14] the
13 fibrosis distribution was as follows: F0 (0.8%), F1 (45.5%), F2 (41.3%), F3 (9.9%), and F4 (2.5%),
14 respectively. Co-infection with HBV or HIV was not included. Due to the small proportion of
15 treatment-experienced patients, only the treatment-naïve patients were considered.
16
17

18 **Model structure and assumptions**

19
20 The structure of the model was based on other models of HCV disease which have been published and
21 validated in health economic analyses.[15-17] The model consisted of 14 health states (Fig.1). Fibrosis
22 stage was defined by the METAVIR fibrosis scoring system and it was assumed that patients enter the
23 model with a given fibrosis score: F0, F1, F2, F3, F4. Patients may develop the more serious liver
24 fibrosis, advanced liver disease (i.e., DC, HCC, LT), or may keep that health state. If patients achieved
25 SVR after the successful treatment, the disease progression was to halt. However, it allowed for the
26 transitions from SVR to DC or HCC for patients with cirrhosis (F4) at a lower rate. Patients at the stage
27 of compensated cirrhosis (F4) were at risk of developing DC or HCC. If a patient developed DC and/or
28 HCC, then the patient may receive a liver transplant. Patients with advance liver disease had higher
29 mortality rates than other patients. All the other patients had the same mortality rate as the general
30 population.
31
32

33
34 It was assumed that there was no disease progression during treatment. Only cirrhotic patients (F4)
35 could progress to DC and HCC and it still had risk of DC and HCC even if they achieved SVR.
36 Adverse events were not considered due to the minimal rates in these interferon-free regimens.
37
38

39 **Model comparators and clinical inputs**

40
41 DCV+ASV, SOF/VEL, EBR/GZR, 3D and SOF-based regimens (SR: the combination of sofosbuvir
42 and RBV; SD: the combination of sofosbuvir and dasabuvir) are all recommended for chronic GT1b
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 infection in the Chinese setting. The duration of DCV+ASV and SR are 24 weeks, and for the other
5 three regimens are 12 weeks. The treatment effectiveness was defined as SVR. The SVRs of
6 DCV+ASV, SOF/VEL, EBR/GZR, 3D were derived from international multicenter clinical
7 trials.[18-22] The SVR of SD was derived from a systematic review.[23] The SVR of SR was obtained
8 from a clinical trial in the Chinese setting.[24] The clinical inputs are shown in Table 1.
9
10
11
12

13 **Transition probabilities**

14
15 The transition probabilities are shown in Table 1. The rates of fibrosis progression between F0 to F4
16 were derived from a meta-analysis.[25] The probability from F4 to DC and HCC and from DC to HCC
17 were estimated from published literature.[26,27] Patients achieving SVR were assumed to develop DC
18 or HCC at a lower rate according to a prospective study.[28] The probabilities of liver transplantation
19 of DC or HCC were obtained from published studies, in which the proportion of liver transplantation
20 was derived from a previous study and was adjusted based on the donation rate ratio between Chinese
21 (0.6 per million) and individuals of Western countries (34.4 per million).[29] The mortality rates
22 associated with DC, HCC, liver transplantation in first year and liver transplantation in subsequent
23 years, which were higher than general mortality, were sourced from the published literature.[28,30]
24 Age-specific all-cause mortality rates were obtained from the life tables of the World Health
25 Organization (WHO) member states.
26
27
28
29
30
31
32
33
34
35

36 **Direct medical costs**

37
38 The Chinese healthcare perspective was adopted in this study. All costs were inflated to 2019 using the
39 China Consumer Price Index and converted to US dollars using official exchange rates as of 2019 (1
40 USD=6.90 CNY). The medical costs consisted of drug costs and liver-related health state costs (Table
41 1). Drug costs were based on local charges without discounts as the DAAs have not been reimbursed in
42 social health insurance system of China. The annual costs of F0-F4, DC, HCC were derived from a
43 survey of HCV-infected patients in China, which included costs of liver-related care (e.g., laboratory
44 tests, procedures, medications, and hospitalizations).[31] The annual costs associated with liver
45 transplant and post-liver transplant were obtained from a study in the context of China.[32] Patients
46 after SVR were assumed to incur no medical costs. Future costs were discounted at 5% per year.
47
48
49
50
51
52
53
54
55

56 **Health utilities**

57
58 Utility weights for each health state of liver disease were mainly obtained from a published systematic
59
60

1
2
3
4 review.[33] The quality of life (QOL) of patients with SVR was based on a published study.[34]
5
6 Disutility was not considered during the therapy. The utilities are shown in table 1.

7 8 **Model analysis**

9
10 Costs and quality-adjusted life years (QALYs) were discounted at 5% per year. Incremental cost-utility
11
12 ratios (ICURs) were reported to show cost-utility of SOF/VEL regimen relative to the comparator. We
13
14 calculated ICURs by dividing the incremental costs by the incremental QALYs for the SOF/VEL
15
16 regimen compared each of the comparators. In cases in which the SOF/VEL regimen was less costly
17
18 and more effective than a comparator, it was concluded to be economically dominant. In other cases,
19
20 ICURs were reported. US\$28,106/QALY, the three times Chinese gross domestic product (GDP) per
21
22 capita, was used to be the willingness to pay threshold. In cases the ICUR of SOF/VEL was lower than
23
24 US\$28,106/QALY, it was regarded as cost-effective. Otherwise, it was not cost-effective.

25 26 **Sensitivity analysis**

27
28 One-way sensitivity analyses were conducted to test the effect of varying input parameters on the
29
30 ICUR of SOF/VEL treatment regimen compared to the comparator. The efficacy, costs, progression
31
32 rates, utilities, and discount rates were tested under the ranges defined in the inputs tables (Table 1).
33
34 The 95% confidence interval (CI) of each parameter was used to be the varying range; in case the 95%
35
36 CI was not available, the 25% of parameter would be used. In addition, discount rate varied ranging
37
38 from 3% to 5%. The results were presented by tornado diagrams.

39
40 A probabilistic sensitivity analysis (PSA) was conducted in which all the input parameters were varied
41
42 simultaneously. Inputs were sampled from predefined distributions with 1000 iterations (Table 1). The
43
44 key parameters of each specific distribution were calculated from the mean and standard error. Beta
45
46 distribution was applied to transition probabilities and utilities. Gamma distribution was applied to
47
48 costs. Uniform distribution was applied in which the parameters were not available. Results of the PSA
49
50 were presented using cost-effectiveness acceptability curves, which reflect the probability that the
51
52 regimens will be cost effective at various willingness-to-pay thresholds.

53 54 **Results**

55 56 **Base-case analysis**

57
58 Results of the base-case are presented in Table 2. Compared with SD and SR, SOF/VEL was dominant
59
60 with higher effectiveness and lower cost. The ICURs of SOF/VEL versus DCV/ASV was \$1522,

1
2
3
4 which was lower than the threshold of \$28,106 per QALY. The ICURs of SOF/VEL versus EBR/GZR
5 was \$369,627, which exceeded the threshold. Compared with 3D, SOF/VEL was dominated with
6 higher costs and fewer QALYs. All in all, 3D is the most effective strategy in GT1b HCV patients,
7 followed by the EBR/GZR, SOF/VEL strategies.
8
9

10
11 The treatment costs among regimens ranged from \$9,792 to \$19,118 (difference \$9,326) and QALYs
12 ranged from 13.2262 to 13.4435 (difference 0.2173). Costs were lowest for 3D and highest for SR;
13 QALYs were highest for 3D and lowest for DCV/ASV. Compared with sofosbuvir-based regimens (SR
14 and SD), the second-generation DAAs (3D, EBR/GZR, SOF/VEL, DCV/ASV) resulted in fewer costs
15 and more QALYs.
16
17

21 **Deterministic sensitivity analysis**

22
23 The 10 input parameters, to which ICURs were most sensitive, were presented in tornado diagrams
24 (Fig. 2). ICURs were most sensitive to SVR rates and drug costs. However, only the cost of drugs can
25 lead to changes of results. Reducing the cost of SOF/VEL to the lower bound of confidence interval,
26 \$8701, resulted in dominance over EBR/GZR. SOF/VEL was dominated by 3D in the base-analysis,
27 but reducing the cost of SOF/VEL to the lower value of confidence interval of \$7945, resulted in
28 SOF/VEL dominating the comparator of 3D. However, compared to DCV/ASV and SR, SOF/VEL was
29 cost-effective no matter what parameter changes within the given range were.
30
31
32
33
34
35

36 **Probabilistic sensitivity analysis**

37
38 The result of probability sensitivity analysis was consistent with the base-case results. The
39 cost-effectiveness acceptability curve showed that, 3D was to be cost-effective in 100% of the 1000
40 PSA iterations run, at a willingness-to-pay threshold up to \$28,106 per QALY (Fig.3). The
41 probabilities that SOF/VEL and other DAA regimens would be cost-effective were 0%.
42
43
44
45

46 **Discussion**

47
48 This study evaluated the cost-utility of all DAAs used among GT1b HCV patients in China. The
49 base-case results showed that SOF/VEL was economically dominant relative to SR and SD. Compared
50 with DCV/ASV, SOF/VEL was also more cost-effective. However, relative to EBR/GZR, SOF/VEL
51 was not cost-effectiveness in GT1b HCV patients. 3D was dominant over SOF/VEL and all other
52 DAAs regimens.
53
54
55
56
57
58
59
60

1
2
3
4 To our knowledge, this is the first study including all available all-oral DAAs for the treatment of HCV
5 1b patients and comparing the cost-effectiveness of SOF/VEL with all other DAAs in the Chinese
6 setting. It is more comprehensive and practical than previous study. Previous analyses in China have
7 evaluated the cost-effectiveness of DAA regimen in GT1b HCV patients. Chen H et al. and Chen GF et
8 al. compared DAAs with PR;[34,36] however, results of these two analyses may have potential
9 deviation as the drug costs were from foreign countries because DAAs had not been approved in China
10 when they did their studies. In another analysis, Liu et al. conducted the cost-effectiveness of
11 DCV/ASV with PR, and the result showed that DCV/ASV were cost-effective relative to PR-based
12 treatment or general interferon treatment.[29] Another study indicated that EBR/GZR was more
13 cost-effectiveness than DCV/ASV.[37] In addition, Wu et al. evaluated cost-effectiveness of DAAs
14 including DCV/ASV, 3D, SR, SD, which showed 3D was most-effective in Chinese 1b patients.[32]

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
There are several cost-effectiveness studies in other countries comparing the SOF/VEL with other
all-oral DAA treatments. Corman et al. compared SOF/VEL with EBR/GZR, 3D, LDV/SOF by
subtype (GT1a or 1b) and cirrhosis status, the results indicated that SOF/VEL was economically
dominant relative to both 3D and LDV/SOF in GT1b treatment-naïve noncirrhotic patients, whereas
SOF/VEL was dominated by EBR/GZR.[16] In our study, 3D was dominant compared with SOF/VEL,
of which the reason was the cost of 3D was obviously lower than SOF/VEL, contrary to the situation in
America. Another study conducted in India evaluated the cost-effectiveness of SOF/VEL versus
genotype-dependent treatments, the results showed the pan-genotypic SOF/VEL was cost-effective for
HCV treatment compared with genotype-dependent SD or LDV/SOF,[38] which was similar to our
analysis.

The sensitivity analysis demonstrated that drug costs could result in significant impacts on the ICURs
of SOF/VEL, because the cost of SOF/VEL was 18% higher than the least expensive comparators, 3D
and EBR/GZR, and yet the SVR rates difference between these regimens was small. Achieving better
cost-effectiveness of SOF/VEL has significant health policy implications in China, where most of the
HCV patients are from rural areas, mainly in the low-income group, and prone to be impoverished due
to disease. Because medical technologies and equipments in rural areas are relatively constrained, HCV
patients have to go to hospitals in big cities for diagnosis and treatment. Specifically, only large
hospitals in big cities can perform genotyping test. The cost-effectiveness of SOF/VEL may be

1
2
3
4 favorable if great inconvenience and extra direct non-medical expenses in the process of visiting a
5 doctor and curing HCV are considered in the economic evaluation from a broader prospective. Thus, in
6 order to achieve the goal of HCV elimination by 2030 within limited health resources in China, the
7 SOF/VEL regimen, a pan-genotypic DAA treatment, has considerable significances. The
8 pan-genotypic treatment provides ‘an opportunity to simplify the care pathway by removing the need
9 for genotyping and thus simplifying procurement and supply chains’.[35] It does not need to test the
10 genotype and METAVIR fibrosis scores, and can be used in patients with all genotype and all
11 METAVIR fibrosis stages. Treatment simplification of SOF/VEL is of particular significance in
12 achieving the goal of HCV elimination in China and other developing countries with limited resource.
13 As a result, SOF/VEL was listed in the National Essential Medicines List of China in 2018.
14
15

16
17 Although the pan-genotypic treatment, SOF/VEL, could simply the process of HCV treatment, the
18 results of this study indicated that it is not the most cost-effective therapy in treating GT1b HCV
19 Chinese patients from health care system. The conclusion is also driven by another cost parameter: the
20 cost of genotyping test of only \$115 in China, which is trivial in comparison to DAA drug cost. In the
21 resource-limited setting, a possible ideal policy option is to reduce the price of SOF/VEL by the
22 negotiation between government and drug manufacturers, which will make more underserved HCV
23 patients having access to the treatment.
24
25

26
27 The analysis has some limitations. Firstly, SVR rates were from several international multicenter
28 clinical trials due to the absence of the effectiveness of real-world clinical setting in China. Although
29 the DAAs have been available since 2017, we still need some time to get the real-world effectiveness
30 data. The future studies will evaluate the real-world effectiveness when data are available. Secondly,
31 the transition probabilities were also obtained from the international literature, in the absence of
32 Chinese sources, which may result in some bias on our results. Thirdly, the costs were estimated from
33 market prices, the results may differ from the final discounted prices after negotiated agreements.
34 Finally, SOF/VEL may be the most cost-effective treatment in other genotypes; however, our research
35 did not include other genotypes. In future studies, we will include other genotypes to evaluate the
36 cost-effective of SOF/VEL comprehensively.
37
38

39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 **Conclusion** 57 58 59 60

1
2
3
4 This modeling study demonstrated SOF/VEL to be cost-effective compared with SR, SD and
5 DCV/ASV, but not cost-effective versus EBR/GZR and 3D in HCV GT1b patients. The government
6 should negotiate with pharmaceutical companies to bring down the price of SOF/VEL, which will
7 make it cost-effective while simplifying the treatment of HCV and achieving the goal of HCV
8 elimination by 2030.
9
10
11
12

13 **Acknowledgements**

14
15 We would like to acknowledge and thank our cooperation partners (Prof. Qiang Li from Jinan
16 Infectious Disease Hospital and Prof. Lei Wang from the Second Hospital of Shandong University) for
17 their help in data collection.
18
19
20

21 **Patient and Public Involvement**

22
23 Patients or public were not involved.
24

25 **Author contributions**

26
27 YHY and XJS designed the study. YHY, GQZ, and XJS collected the data. YHY performed the
28 analyses. YHY drafted the manuscript. XJS and LZS interpreted the results and edited the manuscript.
29
30 All authors have read and approved the final manuscript.
31
32

33 **Funding**

34
35 This work was supported by Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd. The
36 sponsor did not have any role in the study design, data collection and analysis, decision to publish, or
37 preparation of the manuscript.
38
39
40

41 **Competing interests**

42
43 We have read and understood BMJ policy on declaration of interests and declare that we have no
44 competing interests.
45
46

47 **Provenance and peer review**

48
49 Not commissioned; externally peer reviewed.
50

51 **Data sharing statement**

52
53 No additional data are available.
54

55 **References**

56
57 [1] Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C
58 virus infection in 2015: a modelling study. *The Lancet Gastroenterology & Hepatology*. 2017; 2:
59
60

1
2
3
4 161-76.

5 [2] World Health Organization. Hepatitis C. Fact sheet. [http://](http://www.who.int/mediacentre/factsheets/fs164/en/)
6 www.who.int/mediacentre/factsheets/fs164/en/. Published April 2017. Accessed July 27, 2019.

7
8
9 [3] Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. *Journal of Gastroenterology*
10 *and Hepatology*. 2013; 28: 7-10.

11
12
13 [4] Rao H, Wei L, Lopez-Talavera JC, et al. Distribution and clinical correlates of viral and host
14 genotypes in Chinese patients with chronic hepatitis C virus infection. *Journal of Gastroenterology and*
15 *Hepatology*. 2014; 29: 545-53.

16
17
18 [5] Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based
19 approach. *Alimentary Pharmacology & Therapeutics*. 2014; 39: 518-31.

20
21
22 [6] Razavi H, ElKhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost
23 in the United States. *Hepatology*. 2013; 57: 2164-70.

24
25
26 [7] Simmons B, Saleem J, Heath K, et al. Long-Term Treatment Outcomes of Patients Infected With
27 Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a
28 Sustained Virological Response. *Clin Infect Dis*. 2015; 61: 730-40.

29
30
31 [8] Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a
32 systematic review of the clinical, economic and quality of life benefits. *BMC infectious diseases*. 2015;
33 15: 19.

34
35
36 [9] Chinese Society of Hepatology. The guidelines of prevention and treatment for chronic hepatitis C
37 (2015 updated version). *Chinese Hepatology*. 2015; 33: 192±94.

38
39
40 [10] Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus
41 infection: optimizing current IFN-free treatment and future perspectives. *Liver International*. 2016; 36:
42 47-57.

43
44
45 [11] Asselah T, Marcellin P. Optimal IFN-free therapy in treatment-naïve patients with HCV genotype
46 1 infection. *Liver International*. 2015; 35: 56-64.

47
48 [12] Greig SL. Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C. *Drugs*. 2016; 76: 1567-78.

49
50
51 [13] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. *Hepatology*.
52 1996; 24: 289-93.

53
54
55 [14] Li JF, Liu S, Ren F, et al. Fibrosis progression in interferon treatment-naïve Chinese plasma
56
57
58
59
60

- 1
2
3
4 donors with chronic hepatitis C for 20 years: a cohort study. *Int J Infect Dis.* 2014; 27: 49-53.
- 5
6 [15] Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C
7 virus treatment with sofosbuvir and ledipasvir in the United States. *Ann Intern Med.* 2015; 162:
8 397-406.
- 9
10
11 [16] Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the
12 treatment of hepatitis C virus. *Annals of internal medicine.* 2015; 162: 407-19.
- 13
14 [17] Corman S, Elbasha EH, Michalopoulos SN, et al. Cost-Utility of Elbasvir/Grazoprevir in Patients
15 with Chronic Hepatitis C Genotype 1 Infection. *Value Health.* 2017; 20: 1110-20.
- 16
17 [18] Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5,
18 and 6 Infection. *N Engl J Med.* 2015; 373: 2599-607.
- 19
20 [19] Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir Combination Therapy for
21 Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or
22 6 Infection: A Randomized Trial. *Ann Intern Med.* 2015; 163: 1-13.
- 23
24 [20] Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without
25 ribavirin for HCV. *N Engl J Med.* 2014; 370: 1983-92.
- 26
27 [21] Dore GJ, Conway B, Luo Y, et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir
28 compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
29 *Journal of hepatology.* 2016; 64: 19-28.
- 30
31 [22] Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus
32 genotype 1b: a multinational, phase 3, multicohort study. *The Lancet.* 2014; 384: 1597-605.
- 33
34 [23]Zhu G-Q, Zou Z-L, Zheng J-N, et al. Systematic Review and Network Meta-Analysis of
35 Randomized Controlled Trials. *Medicine.* 2016; 95: e3004.
- 36
37 [24] Wei L, Xie Q, Hou JL, et al. Sofosbuvir plus ribavirin with or without peginterferon for the
38 treatment of hepatitis C virus: Results from a phase 3b study in China. *J Gastroenterol Hepatol.* 2018;
39 33: 1168-76.
- 40
41 [25]Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic
42 hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology.* 2008; 48: 418-31.
- 43
44 [26] Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C:
45 a retrospective follow-up study of 384 patients. *Gastroenterology.* 1997; 112: 463-72.
- 46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 [27] Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in
5 compensated, histologically advanced chronic hepatitis C. *Hepatology*. 2011; 54: 396-405.
6
7 [28] Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C
8 virus-related cirrhosis. A study of 200 patients. *J Hepatol*. 2004; 40: 823-30.
9
10 [29] Liu Y, Wang Z, Tobe RG, et al. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for
11 Chinese Patients with Chronic Hepatitis C Virus Genotype 1b. *Clin Drug Investig*. 2018; 38: 427-37.
12
13 [30] Wolfe RA, Merion RM, Roys EC, et al. Trends in Organ Donation and Transplantation in the
14 United States, 1998–2007. *American Journal of Transplantation*. 2010; 10: 961-72.
15
16 [31] Chen GF, Wei L, Chen J, et al. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and
17 Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using
18 Real-World Data. *PLoS One*. 2016; 11: e0155934.
19
20 [32] Wu B, Wang Z, Xie Q. Cost-effectiveness of novel regimens for Chinese patients with chronic
21 hepatitis C. *Curr Med Res Opin*. 2019; 35: 847-57.
22
23 [33] McIernon DJ, Dillon J, Donnan PT. Systematic Review: Health-State Utilities in Liver Disease: A
24 Systematic Review. *Medical Decision Making*. 2008; 28: 582-92.
25
26 [34] Thein HH, Krahn M, Kaldor JM, et al. Estimation of utilities for chronic hepatitis C from SF-36
27 scores. *Am J Gastroenterol*. 2005; 100: 643-51.
28
29 [35] Organization WH. Guidelines for the care and treatment of persons diagnosed with chronic
30 hepatitis C virus infection. 2018.
31
32 [36] Chen H, Chen L. Estimating cost-effectiveness associated with all-oral regimen for chronic
33 hepatitis C in China. *PLoS One*. 2017; 12: e0175189.
34
35 [37] Chen P, Ma A, Liu Q. Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus
36 Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China. *Clin Drug*
37 *Investig*. 2018; 38: 1031-9.
38
39 [38] Goel A, Chen Q, Chhatwal J, et al. Cost-effectiveness of generic pan-genotypic
40 sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. *J*
41 *Gastroenterol Hepatol*. 2018; 33: 2029-36.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 model inputs

Parameter	Base case	Lower limit	Higher limit	Distribution	Parameter1	Parameter2	Reference
SVR rates							
SOF/VEL, NC	0.984	0.960	0.996	Uniform	0.960	0.996	[17]
SOF/VEL, C	0.958	0.789	0.999	Uniform	0.789	0.999	[17]
EBR/GZR, NC	0.980	0.937	1	Uniform	0.937	1	[18]
EBR/GZR, C	1	0.937	1	Uniform	0.937	1	[18]
3D, NC	0.993	0.976	1	Uniform	0.976	1	[19]
3D, C	0.942	0.892	0.991	Uniform	0.892	0.991	[20]
DCV/ASV, NC	0.889	0.85	0.94	Uniform	0.85	0.94	[21]
DCV/ASV, C	0.911	0.85	0.94	Uniform	0.85	0.94	[21]
SD, NC	0.98	0.95	1	Uniform	0.95	1	[22]
SD, C	0.98	0.95	1	Uniform	0.95	1	[22]
SR, NC	0.94	0.87	0.99	Uniform	0.87	0.99	[23]
SR, C	0.94	0.87	0.99	Uniform	0.87	0.99	[23]
Annual transition probabilities							
Fibrosis progression							
F0-F1	0.117	0.104	0.130	Beta	274.98	2075.30	[24]
F1-F2	0.085	0.075	0.096	Beta	210.06	2261.18	[24]
F2-F3	0.120	0.109	0.133	Beta	288.05	2112.38	[24]
F3-F4	0.116	0.104	0.129	Beta	270.61	2062.22	[24]
Cirrhosis progression							
F4-DC	0.039	0.010	0.079	Beta	3.51	86.48	[25]
F4-HCC	0.014	0.010	0.079	Beta	0.18	12.38	[25]
F4-SVR to DC	0.003	0.002	0.004	Beta	96	31821	[26]
F4-SVR to DC	0.006	0.005	0.007	Beta	95	15814	[26]
Liver disease progression							
DC-HCC	0.068	0.054	0.082	Beta	89	1226	[28]
Receiving liver transplant							
DC-LT	0.0003	0.0002	0.0011	Beta	0	0.1	[28]
HCC-LT	0.0005	0.0	0.0024	Beta	4.1	8788.8	[28]
Mortality rates							
DC-Death	0.129	0.1032	0.5124	Beta	147.03	983.97	[27]
HCC-Death	0.427	0.3416	0.5124	Beta	117.1	155.23	[27]
LT-Death	0.116	0.060	0.420	Beta	1.3	9.9	[29]
PLT-Death	0.044	0.060	0.420	Beta	4.7	101.6	[29]
Drug costs							Local charge
SOF/VEL	10087	7565	12608				

EBR/GZR	8548	6411	10685				
3D	8546	6409	10682				
DCV/ASV	8378	6283	10472				
SD	12302	9226	15377				
SR	17096	12822	21370				
Annual health state costs							
F0-F3	992	671	1313	Gamma	6002	0.165	[30]
F4	2823	1001	4646	Gamma	8570	0.329	[30]
DC	6287	3820	8755	Gamma	31403	0.200	[30]
HCC	13272	9544	17000	Gamma	92610	0.143	[30]
LT(first year)	56719	40983	81956	Gamma	308255	0.184	[31]
LT(subsequent years)	9016	8196	10077	Gamma	170113	0.053	[31]
Utilities							
F0-F3	0.790	0.632	0.948	Beta	19.4	5.2	[32]
F4	0.748	0.598	0.898	Beta	23.5	7.9	[32]
DC	0.672	0.538	0.806	Beta	30.8	15.0	[32]
HCC	0.610	0.488	0.732	Beta	36.8	23.6	[32]
LT(first year)	0.560	0.520	0.780	Beta	33.0	17.8	[32]
LT(subsequent years)	0.709	0.567	0.851	Beta	27.2	11.2	[32]
Post-SVR	0.87	0.65	1	Uniform	0.65	1	[33]

SVR, sustained virologic response; NC, non-cirrhotic; C, cirrhotic; SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir; 3D, ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; VEL, velpatasvir; F0-F4, METAVIR liver fibrosis scores; CC compensated cirrhosis; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplant; PLT, post liver transplant

Table 2 Base case results

Treatment regimen	Discounted costs(\$)	Discounted QALYs	Incremental costs(\$)	Incremental QALYs	ICUR, SOF/VEL(\$/QALY)
SR	19,118	13.3342	-7716	0.0921	Dominant
SD	13,727	13.4207	-2325	0.0056	Dominant
DCV/ASV	11,155	13.2262	247	0.2001	1,234/QALY
3D	9,792	13.4435	1510	-0.0172	dominated
EBR/GZR	9,966	13.4228	1436	0.0040	359,000/QALY
SOF/VEL	11,402	13.4263	-	-	-

Note: SOF/VEL is considered the reference treatment.

1
2
3
4 SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir;
5
6 3D, ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir;
7
8 VEL, velpatasvir; QALY, quality-adjusted life year; ICUR, incremental cost-utility ratio.
9

10 11 **Figure legends**

12
13 Figure 1: model structure. F0-F4: METAVIR liver fibrosis scores; DC, F0-F4, METAVIR liver fibrosis
14
15 scores; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplant(first year);
16
17 PLT, liver transplant (subsequent years); SVR, sustained virologic response.

18
19 Figure 2: Tornado diagrams showed the impact of lower and upper values of each parameter in
20
21 incremental cost-effectiveness ratio of SOF/VEL over other DAAs.

22
23 (a) SOF/VEL vs EBR/GZR. (b) SOF/VEL vs 3D. (c) SOF/VEL vs ASV/DCV. (d) SD vs SOF/VEL.
24
25 (e) SR vs SOF/VEL. The effect of 10 influential variables is shown. Each bar shows the variation in
26
27 ICER, blue color, low value; red color, high value). WTP: willingness to pay; ICER: incremental
28
29 cost-effectiveness ratio; SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV,
30
31 asunaprevir; DCV, daclatasvir; 3D, ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR,
32
33 grazoprevir; SOF, sofosbuvir; VEL, velpatasvir.

34
35 Figure 3 : Acceptability curves comparing the cost-effectiveness of different competing strategies. SR,
36
37 sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir; 3D,
38
39 ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; VEL,
40
41 velpatasvir.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: model structure. F0-F4: METAVIR liver fibrosis scores; DC, F0-F4, METAVIR liver fibrosis scores; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplant(first year); PLT, liver transplant (subsequent years); SVR, sustained virologic response.

256x111mm (300 x 300 DPI)




Figure 2: Tornado diagrams showed the impact of lower and upper values of each parameter in incremental cost-effectiveness ratio of SOF/VEL over other DAAs. (a) SOF/VEL vs EBR/GZR. (b) SOF/VEL vs 3D. (c) SOF/VEL vs ASV/DCV. (d) SD vs SOF/VEL. (e) SR vs SOF/VEL. The effect of 10 influential variables is shown. Each bar shows the variation in ICER, blue color, low value; red color, high value). WTP: willingness to pay; ICER: incremental cost-effectiveness ratio; SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir; 3D, ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; VEL, velpatasvir.

533x444mm (300 x 300 DPI)




Figure 3 : Acceptability curves comparing the cost-effectiveness of different competing strategies. SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir; 3D, ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; VEL, velpatasvir.

282x158mm (300 x 300 DPI)

CHEERS Checklist

Items to include when reporting economic evaluations of health interventions

The **ISPOR CHEERS Task Force Report**, *Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force*, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

Section/item	Item No	Recommendation	Reported on page No/line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.	P1
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	P1
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions.	P2-3
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	P4
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	P3
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	P3
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	P4
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	P3
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	P3
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	P6
Measurement of effectiveness	11a	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	P5



1		11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	P5
2				
3				
4	Measurement and	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	NA
5	valuation of preference			
6	based outcomes			
7				
8	Estimating resources	13a	<i>Single study-based economic evaluation:</i> Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	NA
9	and costs			
10				
11				
12				
13				
14				
15		13b	<i>Model-based economic evaluation:</i> Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	P5
16				
17				
18				
19				
20				
21				
22	Currency, price date,	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.	P5
23	and conversion			
24				
25				
26				
27				
28	Choice of model	15	Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.	P4
29				
30				
31				
32	Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.	P4
33				
34	Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.	P6
35				
36				
37				
38				
39				
40				
41				
42	Results			
43	Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	P6
44				
45				
46				
47				
48				
49	Incremental costs and	19	For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.	P6-7
50	outcomes			
51				
52				
53				
54	Characterising	20a	<i>Single study-based economic evaluation:</i> Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact	
55	uncertainty			
56				
57				
58				
59				
60				



1		of methodological assumptions (such as discount rate, study perspective).	NA
2			
3			
4	20b	<i>Model-based economic evaluation</i> : Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	P7
5			
6			
7	Characterising heterogeneity	21	
8		If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	NA
9			
10			
11			
12			
13	Discussion		
14	Study findings, limitations, generalisability, and current knowledge	22	
15		Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	P7-9
16			
17			
18			
19	Other		
20	Source of funding	23	
21		Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	P10
22			
23			
24	Conflicts of interest	24	
25		Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	P10
26			
27			
28			
29			

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The **ISPOR CHEERS Task Force Report** provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. *Value Health* 2013;16:231-50.



BMJ Open

Cost-Utility of Sofosbuvir/Velpatasvir versus other direct-acting antivirals for Chronic Hepatitis C Genotype 1b Infection in China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035224.R1
Article Type:	Original research
Date Submitted by the Author:	06-Mar-2020
Complete List of Authors:	Yun, Haoya; Shandong University, School of Health Care Management; NHC Key Laboratory of Health Economics and Policy Research (Shandong University) Zhao, Guoqiang; Shandong University, School of Health Care Management; NHC Key Laboratory of Health Economics and Policy Research (Shandong University) Sun, Xiaojie; Shandong University, School of Health Care Management; NHC Key Laboratory of Health Economics and Policy Research (Shandong University) Shi, Lizheng; Tulane University, Department of Health Policy and Management, School of Public Health and Tropical Medicine
Primary Subject Heading:	Health economics
Secondary Subject Heading:	Health economics, Public health
Keywords:	HEALTH ECONOMICS, Hepatology < INTERNAL MEDICINE, Public health < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 Cost-Utility of Sofosbuvir/Velpatasvir versus other direct-acting antivirals for Chronic Hepatitis C
5
6 Genotype 1b Infection in China

7 Haoya Yun^{1,2}, Guoqiang Zhao^{1,2}, Xiaojie Sun^{1,2*}, Lizheng Shi³

9 1 School of Health Care Management, Shandong University, Jinan 250012, China

11 2 NHC Key Laboratory of Health Economics and Policy Research (Shandong University), Jinan
12 250012, China

13
14 3 Department of Health Policy and Management, School of Public Health and Tropical Medicine,
15 Tulane University, New Orleans, LA 70118, USA

17
18
19 ***Correspondence:**

21 Xiaojie Sun, PhD, School of Health Care Management, Shandong University and NHC Key
22 Laboratory of Health Economics and Policy Research (Shandong University). Address: 44 Wenhua Xi
23 Road, Jinan, Shandong Province, 250012, People's Republic of China.

24
25
26 E-mail: xiaojiesun@sdu.edu.cn. Tel: 86-15153169185

27
28
29 **Keywords:** cost-utility, Markov model, sofosbuvir/velpatasvir, chronic hepatitis c

30
31
32 **Word count:** 2852 words

33
34 **Abstract**

35 **Objective** This study aimed to estimate the cost-utility of sofosbuvir/velpatasvir (SOF/VEL) compared
36 with other direct-acting antivirals (DAAs) in Chinese Hepatitis C Virus (HCV) patients.

37
38
39 **Design** A Markov model was developed to estimate the disease progression of HCV patients over a
40 lifetime horizon from the health care system perspective. Efficacy, clinical inputs and utilities were
41 derived from published literature. Drug costs were from the market price survey, and health costs for
42 Markov health states were sourced from a Chinese study. Costs and utilities were discounted at an
43 annual rate of 5%. One-way and probabilistic sensitivity analyses were conducted to test the impact of
44 input parameters on the results.

45
46
47
48
49
50
51 **Interventions** SOF/VEL was compared with sofosbuvir + ribavirin (SR), sofosbuvir + dasabuvir (SD),
52 daclatasvir + asunaprevir (DCV/ASV), ombitasvir/paritaprevir/ritonavir + dasabuvir (3D), and
53 elbasvir/grazoprevir (EBR/GZR).

54
55
56
57 **Primary and secondary outcomes** Costs, quality-adjusted life years (QALYs) and incremental
58 cost-utility ratios (ICURs).

1
2
3
4 **Results** SOF/VEL was economically dominant over SR and SD. However, 3D was economically
5 dominant versus SOF/VEL. Compared to DCV/ASV, SOF/VEL was cost-effective with the ICUR of
6 \$1522 per QALY. Compared to EBR/GZR, it was not cost-effective with the ICUR of \$369,627 per
7 QALY. One-way sensitivity analysis demonstrated that reducing the cost of SOF/VEL to the lower
8 value of confidence interval, resulted in dominance over EBR/GZR and 3D. Probabilistic sensitivity
9 analysis demonstrated that 3D was cost-effective in 100% of iterations in genotype (GT) 1b patients
10 and SOF/VEL was not cost-effective.
11
12

13 **Conclusions** Compared with other oral direct-acting antiviral agents, SOF/VEL treatment was not the
14 most cost-effectiveness option for patients with chronic HCV GT1b in China. Lower the price of
15 SOF/VEL will make it cost-effective while simplifying treatment and achieving the goal of HCV
16 elimination.
17
18

19 **Strengths and limitations of this study**

20 To our knowledge, this is the first study including all available all-oral DAAs for the treatment of HCV
21 GT1b patients and comparing the cost-effectiveness of SOF/VEL with all other DAAs in the Chinese
22 setting.
23
24

25 Some of the parameters were retrieved from published literature due to the absence of the real-world
26 data in China, which may result in some bias on our results.
27
28

29 Only the HCV GT1b was considered in this study, other genotypes were not included, which may
30 restrict the generalibility of findings in this study.
31
32

33 **Introduction**

34 Chronic hepatitis C (CHC) is a major public health problem worldwide. It is estimated that there are
35 around 71 million individuals chronically infected with Hepatitis C Virus (HCV), leading to
36 approximately 399,000 deaths each year.[1, 2] In China, the number of HCV-infected patients was
37 estimated to be approximate 10 million in 2006, and the most prevalent genotype is HCV genotype
38 (GT) 1b (56.8%), followed by GT2 (15.8%) , GT3 (8.7%), and GT6 (5.7%) .[3, 4] The Chinese Center
39 for Disease Control and Prevention reported that the incidence was showing an increasing trend, with
40 an estimated 200,000 new cases annually from 2014 to 2018. The undiagnosed and untreated chronic
41 HCV-infected patients are likely to develop serious liver-related complications such as decompensated
42 cirrhosis (DC) and hepatocellular carcinoma (HCC), leading to substantial clinical and economic
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 burden.[5, 6]

5 The endpoint of treating HCV infection is achieving sustained virologic response (SVR), which can
6 significantly reduce the risk of liver disease progression and avoid conversion to end-stage liver
7 diseases.[7] Patients achieving SVR are associated with lower costs and improved quality of life.[8]
8
9 Therefore, the treatment of HCV and achievement of SVR are of critical significance in reducing the
10 health and economic burdens among CHC patients.
11
12
13
14

15 For decades, the standard of care for HCV-infected patients in china has been based on pegylated
16 interferon plus ribavirin (PR) therapy, which is associated with low efficacy, long treatment durations,
17 poor tolerability and much adverse event rates, especially in cirrhotic patients.[9] The introduction of
18 direct-acting antivirals (DAAs), with improved SVR and fewer side effects, has revolutionized HCV
19 treatment. The latest Chinese guideline has suggested that DAA regimens should be applied if patients
20 could afford medical expenses.[9] In recent years, a range of drugs have been approved for HCV
21 treatment by the Chinese State Food and Drug Administration (CFDA). These all-oral regimens for
22 HCV-infected patients, including sofosbuvir plus ribavirin (SR), sofosbuvir plus daclatasvir (SD),
23 daclatasvir plus asunaprevir (DCV/ASV), ombitasvir/paritaprevir/ritonavir plus dasabuvir (3D),
24 elbasvir/grazoprevir (EBR/GZR), and sofosbuvir/velpatasvir (SOF/VEL), have been currently available
25 in China. All these interferon-free regimens resulted in higher efficacy and shorter duration, compared
26 with interferon-based regimens.[10,11] Specially, SOF/VEL was listed in the National Essential
27 Medicines List of China as the only full-oral, direct anti-HCV drug in 2018. Unlike other DAAs,
28 SOF/VEL is a pan-genotypic drug, which is the first fixed-dosage regimen able to achieve high rates of
29 SVR, after only 12 weeks of treatment across all genotypes, all fibrosis scores and typologies of
30 patients.[12]
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 At the present, it is not clear whether SOF/VEL is cost-effective in Chinese HCV GT1b patients.
47
48 Therefore, the objective of this study was to estimate the cost-effectiveness of SOF/VEL compared
49 with other available DAA regimens for treatment of hepatitis HCV GT1b patients.
50
51

52 **Methods**

53
54 The Markov model can simulate the progression of HCV patient through the natural history of HCV
55 and treatment. We used a state-transition Markov model to estimate the economic benefits of SOF/VEL
56 regimen in Chinese patients with HCV GT1b, from the health care system perspective. The model
57
58
59
60

1
2
3
4 simulated the disease progression of HCV patients who received treatment with SOF/VEL or
5 comparators. The model used an annual cycle length and a lifetime horizon. A discount rate of 5% was
6 used for costs and utilities in this model, which was based on the recommendations in the China
7 guideline for pharmacoeconomic evaluations.
8
9
10

11 **Patients characteristics**

12
13 The base-case population in the model represented treatment-naive patients infected with HCV GT1b,
14 the major genotype in China. According to a Chinese study, the mean age of Chinese HCV-infected
15 patients were 44.5 years,[4] so it was assumed that the patients entered the model at the age of 45 years
16 old in this study. The baseline distribution was defined by the METAVIR fibrosis stages: no fibrosis
17 (F0), portal fibrosis with no septa (F1), portal fibrosis with few septa (F2), numerous septa without
18 cirrhosis (F3), and compensated cirrhosis (F4).[13] Based on another Chinese investigation,[14] the
19 fibrosis distribution was as follows: F0 (0.8%), F1 (45.5%), F2 (41.3%), F3 (9.9%), and F4 (2.5%),
20 respectively. Co-infection with HBV or HIV was not included. Due to the small proportion of
21 treatment-experienced patients, only the treatment-naïve patients were considered.
22
23
24
25
26
27
28
29
30

31 **Model structure and assumptions**

32
33 The structure of the model was based on other models of HCV disease which have been published and
34 validated in health economic analyses.[15-17] The model consisted of 14 health states (Fig.1). Fibrosis
35 stage was defined by the METAVIR fibrosis scoring system and it was assumed that patients enter the
36 model with a given fibrosis score: F0, F1, F2, F3, F4. Patients may develop the more serious liver
37 fibrosis, advanced liver disease (i.e., DC, HCC, LT), or may keep that health state. If patients achieved
38 SVR after the successful treatment, the disease progression was to halt. However, it allowed for the
39 transitions from SVR to DC or HCC for patients with cirrhosis (F4) at a lower rate. Patients at the stage
40 of compensated cirrhosis (F4) were at risk of developing DC or HCC. If a patient developed DC and/or
41 HCC, then the patient may receive a liver transplant. Patients with advance liver disease had higher
42 mortality rates than other patients. All the other patients had the same mortality rate as the general
43 population.
44
45
46
47
48
49
50
51
52
53

54 It was assumed that there was no disease progression during treatment. Only cirrhotic patients (F4)
55 could progress to DC and HCC and it still had risk of DC and HCC even if they achieved SVR.
56 Adverse events were not considered due to the minimal rates in these interferon-free regimens.
57
58
59
60

Model comparators and clinical inputs

DCV+ASV, SOF/VEL, EBR/GZR, 3D and SOF-based regimens (SR: the combination of sofosbuvir and RBV; SD: the combination of sofosbuvir and dasabuvir) are all recommended for chronic GT1b infection in the Chinese setting. The duration of DCV+ASV and SR are 24 weeks, and for the other three regimens are 12 weeks. The treatment effectiveness was defined as SVR. The SVRs of DCV+ASV, SOF/VEL, EBR/GZR, 3D were derived from international multicenter clinical trials.[18-22] The SVR of SD was derived from a systematic review.[23] The SVR of SR was obtained from a clinical trial in the Chinese setting.[24] The clinical inputs are shown in Table 1.

Transition probabilities

The transition probabilities are shown in Table 1. The rates of fibrosis progression between F0 to F4 were derived from a meta-analysis.[25] The probability from F4 to DC and HCC and from DC to HCC were estimated from published literature.[26,27] Patients achieving SVR were assumed to develop DC or HCC at a lower rate according to a prospective study.[28] The probabilities of liver transplantation of DC or HCC were obtained from published studies, in which the proportion of liver transplantation was derived from a previous study and was adjusted based on the donation rate ratio between Chinese (0.6 per million) and individuals of Western countries (34.4 per million).[29] The mortality rates associated with DC, HCC, liver transplantation in first year and liver transplantation in subsequent years, which were higher than general mortality, were sourced from the published literature.[28,30] Age-specific all-cause mortality rates were obtained from the life tables of the World Health Organization (WHO) member states.

Direct medical costs

The Chinese healthcare perspective was adopted in this study. All costs were inflated to 2019 using the China Consumer Price Index and converted to US dollars using official exchange rates as of 2019 (1 USD=6.90 CNY). The medical costs consisted of drug costs and liver-related health state costs (Table 1). Drug costs were based on local charges without discounts because the majority of DAAs were not included in the national drug reimbursement list. The annual costs of F0-F4, DC, HCC were derived from a survey of HCV-infected patients in China, which included costs of liver-related care (e.g., laboratory tests, procedures, medications, and hospitalizations).[31] The annual costs associated with liver transplant and post-liver transplant were obtained from a study in the context of China.[32]

1
2
3
4 Patients after SVR were assumed to incur no medical costs. Future costs were discounted at 5% per
5
6 year.

7 **Health utilities**

8
9 Utility weights for each health state of liver disease were mainly obtained from a published systematic
10
11 review.[33] The quality of life (QOL) of patients with SVR was based on a published study.[34]
12
13 Disutility was not considered during the therapy. The utilities are shown in table 1.
14

15 **Model analysis**

16
17 Costs and quality-adjusted life years (QALYs) were discounted at 5% per year. Incremental cost-utility
18
19 ratios (ICURs) were reported to show cost-utility of SOF/VEL regimen relative to the comparator. We
20
21 calculated ICURs by dividing the incremental costs by the incremental QALYs for the SOF/VEL
22
23 regimen compared each of the comparators. In cases in which the SOF/VEL regimen was less costly
24
25 and more effective than a comparator, it was concluded to be economically dominant. In other cases,
26
27 ICURs were reported. US28,106/QALY, the three times Chinese gross domestic product (GDP) per
28
29 capita, was used to be the willingness to pay threshold. In cases the ICUR of SOF/VEL was lower than
30
31 US28,106/QALY, it was regarded as cost-effective. Otherwise, it was not cost-effective.
32

33 **Sensitivity analysis**

34
35 One-way sensitivity analyses were conducted to test the effect of varying input parameters on the
36
37 ICUR of SOF/VEL treatment regimen compared to the comparator. The efficacy, costs, progression
38
39 rates, utilities, and discount rates were tested under the ranges defined in the inputs tables (Table 1).
40
41 The 95% confidence interval (CI) of each parameter was used to be the varying range; in case the 95%
42
43 CI was not available, the 25% of parameter would be used. In addition, discount rate varied ranging
44
45 from 3% to 5%. The results were presented by tornado diagrams.

46
47 A probabilistic sensitivity analysis (PSA) was conducted in which all the input parameters were varied
48
49 simultaneously. Inputs were sampled from predefined distributions with 1000 iterations (Table 1). The
50
51 key parameters of each specific distribution were calculated from the mean and standard error. Beta
52
53 distribution was applied to transition probabilities and utilities. Gamma distribution was applied to
54
55 costs. Uniform distribution was applied in which the parameters were not available. Results of the PSA
56
57 were presented using cost-effectiveness acceptability curves, which reflect the probability that the
58
59 regimens will be cost effective at various willingness-to-pay thresholds.
60

Patient and public involvement

The research study did not involve any direct patient and public involvement.

Results

Base-case analysis

Results of the base-case are presented in Table 2. Compared with SD and SR, SOF/VEL was dominant with higher effectiveness and lower cost. The ICURs of SOF/VEL versus DCV/ASV was \$1522, which was lower than the threshold of \$28,106 per QALY. The ICURs of SOF/VEL versus EBR/GZR was \$369,627, which exceeded the threshold. Compared with 3D, SOF/VEL was dominated with higher costs and fewer QALYs. All in all, 3D is the most effective strategy in GT1b HCV patients, followed by the EBR/GZR, SOF/VEL strategies.

The treatment costs among regimens ranged from \$9,792 to \$19,118 (difference \$9,326) and QALYs ranged from 13.2262 to 13.4435 (difference 0.2173). Costs were lowest for 3D and highest for SR; QALYs were highest for 3D and lowest for DCV/ASV. Compared with sofosbuvir-based regimens (SR and SD), the second-generation DAAs (3D, EBR/GZR, SOF/VEL, DCV/ASV) resulted in fewer costs and more QALYs.

Deterministic sensitivity analysis

The 10 input parameters, to which ICURs were most sensitive, were presented in tornado diagrams (Fig. 2). ICURs were most sensitive to SVR rates and drug costs. However, only the cost of drugs can lead to changes of results. Reducing the cost of SOF/VEL to the lower bound of confidence interval, \$8701, resulted in dominance over EBR/GZR. SOF/VEL was dominated by 3D in the base-analysis, but reducing the cost of SOF/VEL to the lower value of confidence interval of \$7945, resulted in SOF/VEL dominating the comparator of 3D. However, compared to DCV/ASV and SR, SOF/VEL was cost-effective no matter what parameter changes within the given range were.

Probabilistic sensitivity analysis

The result of probability sensitivity analysis was consistent with the base-case results. The cost-effectiveness acceptability curve showed that, 3D was to be cost-effective in 100% of the 1000 PSA iterations run, at a willingness-to-pay threshold up to \$28,106 per QALY (Fig.3). The probabilities that SOF/VEL and other DAA regimens would be cost-effective were 0%.

Discussion

1
2
3
4 This study evaluated the cost-utility of all DAAs used among GT1b HCV patients in China. The
5 base-case results showed that SOF/VEL was economically dominant relative to SR and SD. Compared
6 with DCV/ASV, SOF/VEL was also more cost-effective. However, relative to EBR/GZR, SOF/VEL
7 was not cost-effectiveness in GT1b HCV patients. 3D was dominant over SOF/VEL and all other
8 DAAs regimens.
9
10
11

12
13 To our knowledge, this is the first study including all available all-oral DAAs for the treatment of HCV
14 1b patients and comparing the cost-effectiveness of SOF/VEL with all other DAAs in the Chinese
15 setting. It is more comprehensive and practical than previous study. Previous analyses in China have
16 evaluated the cost-effectiveness of DAA regimen in GT1b HCV patients. Chen H et al. and Chen GF et
17 al. compared DAAs with PR;[34-35] however, results of these two analyses may have potential
18 deviation as the drug costs were from foreign countries because DAAs had not been approved in China
19 when they did their studies. In another analysis, Liu et al. conducted the cost-effectiveness of
20 DCV/ASV with PR, and the result showed that DCV/ASV were cost-effective relative to PR-based
21 treatment or general interferon treatment.[29] Another study indicated that EBR/GZR was more
22 cost-effectiveness than DCV/ASV.[36] In addition, Wu et al. evaluated cost-effectiveness of DAAs
23 including DCV/ASV, 3D, SR, SD, which showed 3D was most-effective in Chinese 1b patients.[32]
24
25
26
27
28
29
30
31
32
33

34 There are several cost-effectiveness studies in other countries comparing the SOF/VEL with other
35 all-oral DAA treatments. Corman et al. compared SOF/VEL with EBR/GZR, 3D, LDV/SOF by
36 subtype (GT1a or 1b) and cirrhosis status, the results indicated that SOF/VEL was economically
37 dominant relative to both 3D and LDV/SOF in GT1b treatment-naïve noncirrhotic patients, whereas
38 SOF/VEL was dominated by EBR/GZR.[16] In our study, 3D was dominant compared with SOF/VEL,
39 of which the reason was the cost of 3D was obviously lower than SOF/VEL, contrary to the situation in
40 America. Another study conducted in India evaluated the cost-effectiveness of SOF/VEL versus
41 genotype-dependent treatments, the results showed the pan-genotypic SOF/VEL was cost-effective for
42 HCV treatment compared with genotype-dependent SD or LDV/SOF,[37] which was similar to our
43 analysis.
44
45
46
47
48
49
50
51
52
53

54 The sensitivity analysis demonstrated that drug costs could result in significant impacts on the ICURs
55 of SOF/VEL, because the cost of SOF/VEL was 18% higher than the least expensive comparators, 3D
56 and EBR/GZR, and yet the SVR rates difference between these regimens was small. Achieving better
57
58
59
60

1
2
3
4 cost-effectiveness of SOF/VEL has significant health policy implications in China, where most of the
5 HCV patients are from rural areas, mainly in the low-income group, and prone to be impoverished due
6 to disease. Because medical technologies and equipment in rural areas are relatively constrained, HCV
7 patients have to go to hospitals in big cities for diagnosis and treatment. Specifically, only large
8 hospitals in big cities can perform genotyping test. The cost-effectiveness of SOF/VEL may be
9 favorable if great inconvenience and extra direct non-medical expenses in the process of visiting a
10 doctor and curing HCV are considered in the economic evaluation from a broader prospective. Thus, in
11 order to achieve the goal of HCV elimination by 2030 within limited health resources in China, the
12 SOF/VEL regimen, a pan-genotypic DAA treatment, has considerable significances. The
13 pan-genotypic treatment provides 'an opportunity to simplify the care pathway by removing the need
14 for genotyping and thus simplifying procurement and supply chains'.^[38] It does not need to test the
15 genotype and METAVIR fibrosis scores, and can be used in patients with all genotype and all
16 METAVIR fibrosis stages. Treatment simplification of SOF/VEL is of particular significance in
17 achieving the goal of HCV elimination in China and other developing countries with limited resource.
18 As a result, SOF/VEL was listed in the National Essential Medicines List of China in 2018.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33 Although the pan-genotypic treatment, SOF/VEL, could simply the process of HCV treatment, the
34 results of this study indicated that it is not the most cost-effective therapy in treating GT1b HCV
35 Chinese patients from health care system. The conclusion is also driven by another cost parameter: the
36 cost of genotyping test of only \$115 in China, which is trivial in comparison to DAA drug cost. If the
37 price of SOF/VEL can be reduced to a reasonable level, more patients will afford this drug, which will
38 make more patients be treated and cured. In addition, it will save much costs for medical insurance
39 payer. In the resource-limited setting, a possible ideal policy option is to reduce the price of SOF/VEL
40 by the negotiation between government and drug manufacturers, which will make more underserved
41 HCV patients having access to the treatment. It will be a triple win situation for medical insurance
42 payer, drug companies and patients.

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The analysis has some limitations. Firstly, SVR rates were from several international multicenter
clinical trials due to the absence of the effectiveness of real-world clinical setting in China. Although
the DAAs have been available since 2017, we still need some time to get the real-world effectiveness
data. The future studies will evaluate the real-world effectiveness when data are available. Secondly,

1
2
3
4 the transition probabilities were also obtained from the international literature, in the absence of
5 Chinese sources, which may result in some bias on our results. Thirdly, the costs were estimated from
6 market prices, and the results may differ from the final discounted prices after negotiated agreements.
7
8 In addition, SOF/VEL may be the most cost-effective treatment in other genotypes; however, our
9 research did not include other genotypes. In future studies, we will include other genotypes to evaluate
10 the cost-effective of SOF/VEL comprehensively. Finally, the lifetime model was built to simulate the
11 progression of HCV, and the benefits of treatment in preventing transmission was not considered,
12 which may have underestimated the value of HCV treatment.
13
14
15
16
17
18

19 **Conclusion**

20
21 This modeling study demonstrated SOF/VEL to be cost-effective compared with SR, SD and
22 DCV/ASV, but not cost-effective versus EBR/GZR and 3D in HCV GT1b patients. The government
23 should negotiate with pharmaceutical companies to bring down the price of SOF/VEL, which will
24 make it cost-effective while simplifying the treatment of HCV and achieving the goal of HCV
25 elimination by 2030.
26
27
28
29

30 **Acknowledgements**

31
32 We would like to acknowledge and thank our cooperation partners (Prof. Qiang Li from Jinan
33 Infectious Disease Hospital and Prof. Lei Wang from the Second Hospital of Shandong University) for
34 their help in data collection.
35
36
37

38 **Patient and Public Involvement**

39
40 Patients or public were not involved.
41

42 **Author contributions**

43
44 YHY and XJS designed the study. YHY, GQZ, and XJS collected the data. YHY performed the
45 analyses. YHY drafted the manuscript. XJS and LZS interpreted the results and edited the manuscript.
46
47 All authors have read and approved the final manuscript.
48
49

50 **Funding**

51
52 This work was supported by Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd. The
53 sponsor did not have any role in the study design, data collection and analysis, decision to publish, or
54 preparation of the manuscript.
55
56
57

58 **Competing interests**

We have read and understood BMJ policy on declaration of interests and declare that we have no competing interests.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional data are available.

References

- [1] Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *The Lancet Gastroenterology & Hepatology*. 2017; 2: 161-76.
- [2] World Health Organization. Hepatitis C. Fact sheet. <http://www.who.int/mediacentre/factsheets/fs164/en/>. Published April 2017. Accessed July 27, 2019.
- [3] Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. *Journal of Gastroenterology and Hepatology*. 2013; 28: 7-10.
- [4] Rao H, Wei L, Lopez-Talavera JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. *Journal of Gastroenterology and Hepatology*. 2014; 29: 545-53.
- [5] Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based approach. *Alimentary Pharmacology & Therapeutics*. 2014; 39: 518-31.
- [6] Razavi H, ElKhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. *Hepatology*. 2013; 57: 2164-70.
- [7] Simmons B, Saleem J, Heath K, et al. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. *Clin Infect Dis*. 2015; 61: 730-40.
- [8] Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. *BMC infectious diseases*. 2015; 15: 19.
- [9] Chinese Society of Hepatology. The guidelines of prevention and treatment for chronic hepatitis C (2015 updated version). *Chinese Hepatology*. 2015; 33: 192±94.

- 1
2
3
4 [10] Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus
5 infection: optimizing current IFN-free treatment and future perspectives. *Liver International*. 2016; 36:
6 47-57.
7
8
9 [11] Asselah T, Marcellin P. Optimal IFN-free therapy in treatment-naïve patients with HCV genotype
10 1 infection. *Liver International*. 2015; 35: 56-64.
11
12 [12] Greig SL. Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C. *Drugs*. 2016; 76: 1567-78.
13
14 [13] Bedossa P, Poinard T. An algorithm for the grading of activity in chronic hepatitis C. *Hepatology*.
15 1996; 24: 289-93.
16
17 [14] Li JF, Liu S, Ren F, et al. Fibrosis progression in interferon treatment-naïve Chinese plasma
18 donors with chronic hepatitis C for 20 years: a cohort study. *Int J Infect Dis*. 2014; 27: 49-53.
19
20 [15] Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C
21 virus treatment with sofosbuvir and ledipasvir in the United States. *Ann Intern Med*. 2015; 162:
22 397-406.
23
24 [16] Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the
25 treatment of hepatitis C virus. *Annals of internal medicine*. 2015; 162: 407-19.
26
27 [17] Corman S, Elbasha EH, Michalopoulos SN, et al. Cost-Utility of Elbasvir/Grazoprevir in Patients
28 with Chronic Hepatitis C Genotype 1 Infection. *Value Health*. 2017; 20: 1110-20.
29
30 [18] Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5,
31 and 6 Infection. *N Engl J Med*. 2015; 373: 2599-607.
32
33 [19] Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir Combination Therapy for
34 Treatment-Naïve Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or
35 6 Infection: A Randomized Trial. *Ann Intern Med*. 2015; 163: 1-13.
36
37 [20] Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without
38 ribavirin for HCV. *N Engl J Med*. 2014; 370: 1983-92.
39
40 [21] Dore GJ, Conway B, Luo Y, et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir
41 compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
42 *Journal of hepatology*. 2016; 64: 19-28.
43
44 [22] Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus
45 genotype 1b: a multinational, phase 3, multicohort study. *The Lancet*. 2014; 384: 1597-605.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 [23]Zhu G-Q, Zou Z-L, Zheng J-N, et al. Systematic Review and Network Meta-Analysis of
5 Randomized Controlled Trials. *Medicine*. 2016; 95: e3004.
6
7
8 [24] Wei L, Xie Q, Hou JL, et al. Sofosbuvir plus ribavirin with or without peginterferon for the
9 treatment of hepatitis C virus: Results from a phase 3b study in China. *J Gastroenterol Hepatol*. 2018;
10 33: 1168-76.
11
12
13 [25]Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic
14 hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology*. 2008; 48: 418-31.
15
16
17 [26] Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C:
18 a retrospective follow-up study of 384 patients. *Gastroenterology*. 1997; 112: 463-72.
19
20
21 [27] Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in
22 compensated, histologically advanced chronic hepatitis C. *Hepatology*. 2011; 54: 396-405.
23
24
25 [28] Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C
26 virus-related cirrhosis. A study of 200 patients. *J Hepatol*. 2004; 40: 823-30.
27
28
29 [29] Liu Y, Wang Z, Tobe RG, et al. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for
30 Chinese Patients with Chronic Hepatitis C Virus Genotype 1b. *Clin Drug Investig*. 2018; 38: 427-37.
31
32
33 [30] Wolfe RA, Merion RM, Roys EC, et al. Trends in Organ Donation and Transplantation in the
34 United States, 1998–2007. *American Journal of Transplantation*. 2010; 10: 961-72.
35
36
37 [31] Chen GF, Wei L, Chen J, et al. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and
38 Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using
39 Real-World Data. *PLoS One*. 2016; 11: e0155934.
40
41
42 [32] Wu B, Wang Z, Xie Q. Cost-effectiveness of novel regimens for Chinese patients with chronic
43 hepatitis C. *Curr Med Res Opin*. 2019; 35: 847-57.
44
45
46 [33] McLernon DJ, Dillon J, Donnan PT. Systematic Review: Health-State Utilities in Liver Disease: A
47 Systematic Review. *Medical Decision Making*. 2008; 28: 582-92.
48
49
50 [34] Thein HH, Krahn M, Kaldor JM, et al. Estimation of utilities for chronic hepatitis C from SF-36
51 scores. *Am J Gastroenterol*. 2005; 100: 643-51.
52
53
54 [35] Chen H, Chen L. Estimating cost-effectiveness associated with all-oral regimen for chronic
55 hepatitis C in China. *PLoS One*. 2017; 12: e0175189.
56
57
58 [36] Chen P, Ma A, Liu Q. Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus
59
60

Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China. *Clin Drug Investig.* 2018; 38: 1031-9.

[37] Goel A, Chen Q, Chhatwal J, et al. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. *J Gastroenterol Hepatol.* 2018; 33: 2029-36.

[38] Organization WH. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018.

Table 1 model inputs

Parameter	Base case	Lower limit	Higher limit	Distribution	Parameter1	Parameter2	Reference
SVR rates							
SOF/VEL, NC	0.984	0.960	0.996	Uniform	0.960	0.996	[18]
SOF/VEL, C	0.958	0.789	0.999	Uniform	0.789	0.999	[18]
EBR/GZR, NC	0.980	0.937	1	Uniform	0.937	1	[19]
EBR/GZR, C	1	0.937	1	Uniform	0.937	1	[19]
3D, NC	0.993	0.976	1	Uniform	0.976	1	[20]
3D, C	0.942	0.892	0.991	Uniform	0.892	0.991	[21]
DCV/ASV, NC	0.889	0.85	0.94	Uniform	0.85	0.94	[22]
DCV/ASV, C	0.911	0.85	0.94	Uniform	0.85	0.94	[22]
SD, NC	0.98	0.95	1	Uniform	0.95	1	[23]
SD, C	0.98	0.95	1	Uniform	0.95	1	[23]
SR, NC	0.94	0.87	0.99	Uniform	0.87	0.99	[24]
SR, C	0.94	0.87	0.99	Uniform	0.87	0.99	[24]
Annual transition probabilities							
Fibrosis progression							
F0-F1	0.117	0.104	0.130	Beta	274.98	2075.30	[25]
F1-F2	0.085	0.075	0.096	Beta	210.06	2261.18	[25]
F2-F3	0.120	0.109	0.133	Beta	288.05	2112.38	[25]
F3-F4	0.116	0.104	0.129	Beta	270.61	2062.22	[25]
Cirrhosis progression							
F4-DC	0.039	0.010	0.079	Beta	3.51	86.48	[26]
F4-HCC	0.014	0.010	0.079	Beta	0.18	12.38	[26]
F4-SVR to DC	0.003	0.002	0.004	Beta	96	31821	[27]

F4-SVR	to	0.006	0.005	0.007	Beta	95	15814	[27]
DC								
Liver disease progression								
DC-HCC		0.068	0.054	0.082	Beta	89	1226	[28]
Receiving liver transplant								
DC-LT		0.0003	0.0002	0.0011	Beta	0	0.1	[29]
HCC-LT		0.0005	0.0	0.0024	Beta	4.1	8788.8	[29]
Mortality rates								
DC-Death		0.129	0.1032	0.5124	Beta	147.03	983.97	[28]
HCC-Death		0.427	0.3416	0.5124	Beta	117.1	155.23	[28]
LT-Death		0.116	0.060	0.420	Beta	1.3	9.9	[30]
PLT-Death		0.044	0.060	0.420	Beta	4.7	101.6	[30]
Drug costs								Local charge
SOF/VEL		10087	7565	12608				
EBR/GZR		8548	6411	10685				
3D		8546	6409	10682				
DCV/ASV		8378	6283	10472				
SD		12302	9226	15377				
SR		17096	12822	21370				
Annual health state costs								
F0-F3		992	671	1313	Gamma	6002	0.165	[31]
F4		2823	1001	4646	Gamma	8570	0.329	[31]
DC		6287	3820	8755	Gamma	31403	0.200	[31]
HCC		13272	9544	17000	Gamma	92610	0.143	[31]
LT(first year)		56719	40983	81956	Gamma	308255	0.184	[32]
LT(subsequen		9016	8196	10077	Gamma	170113	0.053	[32]
t years)								
Utilities								
F0-F3		0.790	0.632	0.948	Beta	19.4	5.2	[33,35]
F4		0.748	0.598	0.898	Beta	23.5	7.9	[33,35]
DC		0.672	0.538	0.806	Beta	30.8	15.0	[33,35]
HCC		0.610	0.488	0.732	Beta	36.8	23.6	[33,35]
LT(first year)		0.560	0.520	0.780	Beta	33.0	17.8	[33,35]
LT(subsequen		0.709	0.567	0.851	Beta	27.2	11.2	[33,35]
t years)								
Post-SVR		0.87	0.65	1	Uniform	0.65	1	[34]

SVR, sustained virologic response; NC, non-cirrhotic; C, cirrhotic; SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir; 3D, ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; VEL, velpatasvir;

F0-F4, METAVIR liver fibrosis scores; CC compensated cirrhosis; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplant; PLT, post liver transplant

Table 2 Base case results

Treatment regimen	Discounted costs(\$)	Discounted QALYs	Incremental costs(\$)	Incremental QALYs	ICUR, SOF/VEL(\$/QALY)
SR	19,118	13.3342	-7716	0.0921	Dominant
SD	13,727	13.4207	-2325	0.0056	Dominant
DCV/ASV	11,155	13.2262	247	0.2001	1,234/QALY
3D	9,792	13.4435	1510	-0.0172	dominated
EBR/GZR	9,966	13.4228	1436	0.0040	359,000/QALY
SOF/VEL	11,402	13.4263	-	-	-

Note: SOF/VEL is considered the reference treatment.

SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir; 3D, ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; VEL, velpatasvir; QALY, quality-adjusted life year; ICUR, incremental cost-utility ratio.

Figure legends

Figure 1: model structure. F0-F4: METAVIR liver fibrosis scores; DC, F0-F4, METAVIR liver fibrosis scores; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplant(first year); PLT, liver transplant (subsequent years); SVR, sustained virologic response.

Figure 2: Tornado diagrams showed the impact of lower and upper values of each parameter in incremental cost-effectiveness ratio of SOF/VEL over other DAAs.

(a) SOF/VEL vs EBR/GZR. (b) SOF/VEL vs 3D. (c) SOF/VEL vs ASV/DCV. (d) SD vs SOF/VEL. (e) SR vs SOF/VEL. The effect of 10 influential variables is shown. Each bar shows the variation in ICER, blue color, low value; red color, high value). WTP: willingness to pay; ICER: incremental cost-effectiveness ratio; SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir; 3D, ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; VEL, velpatasvir.

Figure 3 : Acceptability curves comparing the cost-effectiveness of different competing strategies. SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir; 3D,

1
2
3
4 ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; VEL,
5
6 velpatasvir.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: model structure. F0-F4: METAVIR liver fibrosis scores; DC, F0-F4, METAVIR liver fibrosis scores; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplant(first year); PLT, liver transplant (subsequent years); SVR, sustained virologic response.

256x111mm (300 x 300 DPI)




Figure 2: Tornado diagrams showed the impact of lower and upper values of each parameter in incremental cost-effectiveness ratio of SOF/VEL over other DAAs. (a) SOF/VEL vs EBR/GZR. (b) SOF/VEL vs 3D. (c) SOF/VEL vs ASV/DCV. (d) SD vs SOF/VEL. (e) SR vs SOF/VEL. The effect of 10 influential variables is shown. Each bar shows the variation in ICER, blue color, low value; red color, high value). WTP: willingness to pay; ICER: incremental cost-effectiveness ratio; SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir; 3D, ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; VEL, velpatasvir.

533x444mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3 : Acceptability curves comparing the cost-effectiveness of different competing strategies. SR, sofosbuvir plus ribavirin; SD, sofosbuvir plus daclatasvir; ASV, asunaprevir; DCV, daclatasvir; 3D, ombitasvir/paritaprevir/ritonavir + dasabuvir; EBR, elbasvir; GZR, grazoprevir; SOF, sofosbuvir; VEL, velpatasvir.

282x158mm (350 x 350 DPI)

CHEERS Checklist

Items to include when reporting economic evaluations of health interventions

The **ISPOR CHEERS Task Force Report**, *Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force*, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

Section/item	Item No	Recommendation	Reported on page No/line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.	P1
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	P1
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions.	P2-3
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	P4
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	P3
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	P3
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	P4
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	P3
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	P3
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	P6
Measurement of effectiveness	11a	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	P5



1		11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	P5
2				
3				
4	Measurement and	12	If applicable, describe the population and methods used to	
5	valuation of preference		elicit preferences for outcomes.	NA
6	based outcomes			
7	Estimating resources	13a	<i>Single study-based economic evaluation:</i> Describe approaches	
8	and costs		used to estimate resource use associated with the alternative	
9			interventions. Describe primary or secondary research methods	
10			for valuing each resource item in terms of its unit cost.	
11			Describe any adjustments made to approximate to opportunity	
12			costs.	NA
13				
14		13b	<i>Model-based economic evaluation:</i> Describe approaches and	
15			data sources used to estimate resource use associated with	
16			model health states. Describe primary or secondary research	
17			methods for valuing each resource item in terms of its unit	
18			cost. Describe any adjustments made to approximate to	
19			opportunity costs.	P5
20				
21	Currency, price date,	14	Report the dates of the estimated resource quantities and unit	
22	and conversion		costs. Describe methods for adjusting estimated unit costs to	
23			the year of reported costs if necessary. Describe methods for	
24			converting costs into a common currency base and the	
25			exchange rate.	P5
26				
27	Choice of model	15	Describe and give reasons for the specific type of decision-	
28			analytical model used. Providing a figure to show model	
29			structure is strongly recommended.	P4
30				
31	Assumptions	16	Describe all structural or other assumptions underpinning the	
32			decision-analytical model.	P4
33				
34	Analytical methods	17	Describe all analytical methods supporting the evaluation. This	
35			could include methods for dealing with skewed, missing, or	
36			censored data; extrapolation methods; methods for pooling	
37			data; approaches to validate or make adjustments (such as half	
38			cycle corrections) to a model; and methods for handling	
39			population heterogeneity and uncertainty.	P6
40				
41				
42	Results			
43	Study parameters	18	Report the values, ranges, references, and, if used, probability	
44			distributions for all parameters. Report reasons or sources for	
45			distributions used to represent uncertainty where appropriate.	
46			Providing a table to show the input values is strongly	
47			recommended.	P6
48				
49	Incremental costs and	19	For each intervention, report mean values for the main	
50	outcomes		categories of estimated costs and outcomes of interest, as well	
51			as mean differences between the comparator groups. If	
52			applicable, report incremental cost-effectiveness ratios.	
53				P6-7
54	Characterising	20a	<i>Single study-based economic evaluation:</i> Describe the effects	
55	uncertainty		of sampling uncertainty for the estimated incremental cost and	
56			incremental effectiveness parameters, together with the impact	
57				
58				
59				
60				

		of methodological assumptions (such as discount rate, study perspective).	NA
	20b	<i>Model-based economic evaluation</i> : Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.	P7
Characterising heterogeneity	21	If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.	NA
Discussion			
Study findings, limitations, generalisability, and current knowledge	22	Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.	P7-9
Other			
Source of funding	23	Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.	P10
Conflicts of interest	24	Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.	P10

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The **ISPOR CHEERS Task Force Report** provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. *Value Health* 2013;16:231-50.

